Here, we present the case of a patient with lung adenocarcinoma harboring EGFR and somatic BRCA2 mutations, who developed resistance to third-generation EGFR tyrosine kinase inhibitors (TKIs) and subsequently exhibited durable response to Olaparib. This evidence concerns the gene BRCA2 and lung adenocarcinoma.